What was Cigna's repurchase activity through mid-2026?

Cigna repurchased 0.9 million shares for approximately $250 million year-to-date through July 29, 2026, representing an average price of about $277.78 per share. This is disclosed in the company's Q2 2026 earnings release as executed activity, not a new authorization.

How does Cigna execute its share repurchases?

The company uses Rule 10b-18 open-market purchases, Rule 10b5-1 trading plans (which allow pre-planned purchases), and may also conduct privately negotiated transactions. The timing and number of shares repurchased depend on price, market conditions, and competing capital allocation priorities.

Does the 2026 guidance assume continued buybacks?

Yes. The company explicitly states its 2026 adjusted income per share outlook of at least $30.45 includes 'the impact of expected future share repurchases and anticipated 2026 dividends,' though no specific dollar amount or share count is specified.

Was a new buyback authorization announced in this filing?

No. This filing reports execution under an existing program but does not announce a new authorization, expanded program, or disclosed remaining authorization amount. The company maintains discretion to suspend or discontinue repurchases at any time.

What is the share-count impact of these repurchases?

The 0.9 million share reduction against approximately 264.5 million shares outstanding represents a modest 0.34% share-count reduction year-to-date. The cumulative impact on per-share metrics is material but incremental, with the 2026 outlook reflecting forward repurchase assumptions.

CI 8-K Filed 2026-07-30 Execution disclosure

Cigna repurchased 0.9M shares for $250M through July 2026

Health company executes buybacks year-to-date; plans future repurchases under Rule 10b-18 and 10b5-1 trading plans

Shares repurchased900K

Avg price paid$277.78

MechanismRule 10b-18 open-market purcha

What the filing says

The Cigna Group reported in its July 30, 2026 earnings release that it repurchased 0.9 million shares of common stock for approximately $250 million during the year-to-date period through July 29, 2026. The company's 2026 financial outlook explicitly incorporates "the impact of expected future share repurchases and anticipated 2026 dividends."

The filing discloses that share repurchases may be executed "through open market purchases in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, including through Rule 10b5-1 trading plans, or privately negotiated transactions." The company notes that "the timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions, and alternate uses of capital. The share repurchase program may be suspended or discontinued at any time."

No new authorization amount or expanded program was announced in this filing. The repurchase activity represents execution under an existing authorization, with the company maintaining flexibility regarding future repurchase timing and volume.

Year to date through July 29, 2026, the company repurchased 0.9 million shares of common stock for approximately $250 million. — Cigna Group 8-K filing · View on SEC EDGAR →

What this means

Cigna's year-to-date repurchase of 0.9 million shares at an average price of approximately $277.78 per share reflects modest capital deployment toward shareholder returns. With approximately 264.5 million shares outstanding at mid-2026, the 0.9 million share reduction represents roughly 0.34% share-count reduction. The company's outlook incorporates "expected future share repurchases," indicating an ongoing program, though no specific authorization dollar amount or remaining authorization is disclosed in this filing. The flexibility to suspend, adjust timing, or shift capital to other uses reflects standard buy-back program language.

Frequently asked questions

What was Cigna's repurchase activity through mid-2026?: Cigna repurchased 0.9 million shares for approximately $250 million year-to-date through July 29, 2026, representing an average price of about $277.78 per share. This is disclosed in the company's Q2 2026 earnings release as executed activity, not a new authorization.
How does Cigna execute its share repurchases?: The company uses Rule 10b-18 open-market purchases, Rule 10b5-1 trading plans (which allow pre-planned purchases), and may also conduct privately negotiated transactions. The timing and number of shares repurchased depend on price, market conditions, and competing capital allocation priorities.
Does the 2026 guidance assume continued buybacks?: Yes. The company explicitly states its 2026 adjusted income per share outlook of at least $30.45 includes 'the impact of expected future share repurchases and anticipated 2026 dividends,' though no specific dollar amount or share count is specified.
Was a new buyback authorization announced in this filing?: No. This filing reports execution under an existing program but does not announce a new authorization, expanded program, or disclosed remaining authorization amount. The company maintains discretion to suspend or discontinue repurchases at any time.
What is the share-count impact of these repurchases?: The 0.9 million share reduction against approximately 264.5 million shares outstanding represents a modest 0.34% share-count reduction year-to-date. The cumulative impact on per-share metrics is material but incremental, with the 2026 outlook reflecting forward repurchase assumptions.
Can Cigna change or stop its repurchase program?: Yes. The filing explicitly states the program 'may be suspended or discontinued at any time' and execution depends on 'a variety of factors, including price, general business and market conditions, and alternate uses of capital,' giving the company full discretion over timing and volume.

execution healthcare rule-10b-18 rule-10b5-1 mega-cap open-market

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.